Pfizer (Large Cap) Share Target 2025, 2026 To 2035
|
Pfizer Limited |
|||
|
Price: ₹4,792.50 (-3.07%) | ||
| 52 Week Low: ₹3,950.00 52 Week High: ₹6,451.15 |
|||
| Market Capital: 20,602.93 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Pfizer Share Price Target For 2025
- 1.1.1: Pfizer Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Pfizer Share Price Target For 2026
- 1.2.1: Pfizer Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Pfizer Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Pfizer Brief Company Overview
- 4: Pfizer Financial Performance
- 4.0.1: Is Pfizer A Good Buy For Long Term?
Pfizer, a Large Cap company in the Drug Manufacturers - General Industry has delivered 31.7% returns in 5-year with 25.1% profit margin.
To predict the Pfizer's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Pfizer Share Price Target For 2025
The line chart displays the monthly closing prices of Pfizer with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Pfizer shares in 2025, see the table below.
Pfizer Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 5278.0 (+10.13%) | Price Action: 09 Dec 2024 High |
| 2025 Target 2 | 5225.0 (+9.02%) | Price Action: 24 Oct 2024 Low |
| 2025 Target 1 | 5173.25 (+7.94%) | Price Action: 01 Jan 2025 Low |
| Current Price | 4792.50 | Pfizer's share price as of 22 Jan 2025 |
| Stop Loss 1 | 4618.45 (-3.64%) | Price Action: 02 Jul 2024 High |
| Stop Loss 2 | 4572.02 (-4.61%) | Price Action: 20 Feb 2024 Low |
| Stop Loss 3 | 4524.18 (-5.6%) | Price Action: Feb 2022 High |
Short-Term Technical Outlook
Current Technical Position: Pfizer is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹5071.62 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.01% | 6-month: -11.98% | 1-year: +15.06%
Pfizer Share Price Target For 2026
The line chart displays the monthly closing prices of Pfizer with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Pfizer shares in 2026, see the table below.
Pfizer Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 6998.16 (+46.02%) | Price Action: Chart |
| 2026 Target 2 | 6867.67 (+43.3%) | Price Action: Chart |
| 2026 Target 1 | 6799.67 (+41.88%) | Fibonacci Extension Level 64.90% |
| Current Price | 4792.50 | Pfizer's share price as of 22 Jan 2025 |
| Stop Loss 1 | 4332.36 (-9.61%) | Price Action: Sep 2022 High |
| Stop Loss 2 | 4287.0 (-10.55%) | Price Action: 27 Dec 2023 High |
| Stop Loss 3 | 4243.53 (-11.46%) | Price Action: 19 Jan 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Pfizer is currently trading at 33.7% of its 52-week range (₹3950 - ₹6451.15).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +15.06% | 3-year: +12.5% | 5-year: +31.73%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Pfizer Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹4,792.50 | ||
| 2025 | ₹6,083.96 | +26.94% | ₹6,175.22 |
| 2026 | ₹7,139.92 | +17.35% | ₹7,247.02 |
| 2027 | ₹7,735.87 | +8.34% | ₹7,851.91 |
| 2028 | ₹8,968.30 | +15.93% | ₹9,102.82 |
| 2029 | ₹10,882.93 | +21.34% | ₹11,046.17 |
| 2030 | ₹12,786.20 | +17.48% | ₹12,977.99 |
| 2031 | ₹15,137.16 | +18.38% | ₹15,364.22 |
| 2032 | ₹17,067.32 | +12.75% | ₹17,323.33 |
| 2033 | ₹19,190.51 | +12.44% | ₹19,478.37 |
| 2034 | ₹20,988.95 | +9.37% | ₹21,303.78 |
| 2035 | ₹21,703.59 | +3.4% | ₹22,029.14 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Pfizer Brief Company Overview
Pfizer Limited: A Global Pharmaceutical Leader Pfizer Limited is a leading pharmaceutical company in India with a global presence. Established in 1950, it manufactures and markets a diverse range of products across various therapeutic areas. Key Products and...
Services Neuro/Central Nervous System Cardiovascular Oncology Vaccines Vitamins/Minerals/Nutrients Reputation in the Industry Pfizer Limited has built a strong reputation in the pharmaceutical industry for its high-quality products and commitment to innovation. Commitment to Patients The company is dedicated to providing access to affordable, effective treatments that improve the lives of patients worldwide.Pfizer Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 20,602.93 Crore | Market valuation of Pfizer's shares. |
| Revenue (TTM) | 2,193.17 Crore | Total revenue generated by Pfizer over the past twelve months. |
| Net Income (TTM) | +551.32 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +32.13% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +25.13% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-4.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+38% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
2.62 | Company's total debt divided by total shareholder equity. |
| Total Debt | 94.54 Crore | Sum of Pfizer's current & long-term financial obligations. |
| Total Cash | 2,046.7 Crore | Total amount of liquid funds available to Pfizer. |
| Beta | 0.31 | Beta is less than 1 indicating that the Pfizer's price is less volatile than the market. |
Is Pfizer A Good Buy For Long Term?
Pfizer's strong financial performance makes it a compelling long-term investment. Its solid revenue and profit growth indicate a healthy business. The company's manageable debt and strong cash balance further support its financial stability. Despite recent revenue decline, its consistent earnings growth, impressive profit margin, and strong returns over various time frames demonstrate its long-term potential. Overall, Pfizer is a promising stock for investors seeking a well-established and financially sound company with a proven track record of growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
